Share
Effective targeting of PDGFRA-altered high-grade glioma with avapritinib
CANCER CELL
Mayr, L; Neyazi, S; Schwark, K; Trissal, M; Beck, A; Labelle, J; Eder, SK; Weiler-Wichtl, L; Marques, JG; de Biagi, CAO Jr; Lo Cascio, C; Chapman, O; Sridhar, S; Kenkre, R; Dutta, A; Wang, SQ; Wang, J; Hack, O; Nascimento, A; Nguyen, CM; Castellani, S; Rozowsky, JS; Groves, A; Panditharatna, E; Cruzeiro, GAV; Haase, RD; Tabatabai, K; Madlener, S; Wadden, J; Adam, T; Kong, S; Miclea, M; Patel, T; Bruckner, K; Senfter, D; Lämmerer, A; Supko, J; Guntner, AS; Palova, H; Neradil, J; Stepien, N; Lötsch-Gojo, D; Berger, W; Leiss, U; Rosenmayr, V; Dorfer, C; Dieckmann, K; Peyrl, A; Azizi, AA; Baumgartner, A; Slaby, O; Pokorna, P; Clark, LM; Nguyen, QD; Wakimoto, H; Dubois, F; Greenwald, NF; Bandopadhayay, P; Beroukhim, R; Cameron, A; Ligon, K; Kramm, C; Bronsema, A; Bailey, S; Stucklin, AG; Mueller, S; Skrypek, M; Martinez, N; Bowers, DC; Jones, DTW; Jones, C; Jäger, N; Sterba, J; Müllauer, L; Haberler, C; Kumar-Sinha, C; Chinnaiyan, A; Mody, R; Chavez, L; Furtner, J; Koschmann, C; Gojo, J; Filbin, MG, 2025: Effective targeting of PDGFRA-altered high-grade glioma with avapritinib. CANCER CELL 43(4), doi: 10.1016/j.ccell.2025.02.018
Research Groups:
CEITEC authors: